Cargando…

TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma

Subependymomas are benign tumors characteristically encountered in the posterior fossa of adults that show distinct epigenetic profiles assigned to the molecular group “subependymoma, posterior fossa” (PFSE) of the recently established DNA methylation-based classification of central nervous system t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Christian, Thierfelder, Felix, Träger, Malte, Soschinski, Patrick, Müther, Michael, Edelmann, Dominic, Förster, Alexandra, Geiler, Carola, Kim, Hee-yeong, Filipski, Katharina, Harter, Patrick N., Schittenhelm, Jens, Eckert, Franziska, Ntoulias, Georgios, May, Sven-Axel, Stummer, Walter, Onken, Julia, Vajkoczy, Peter, Schüller, Ulrich, Heppner, Frank L., Capper, David, Koch, Arend, Kaul, David, Paulus, Werner, Hasselblatt, Martin, Schweizer, Leonille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113189/
https://www.ncbi.nlm.nih.gov/pubmed/33755803
http://dx.doi.org/10.1007/s00401-021-02300-8
Descripción
Sumario:Subependymomas are benign tumors characteristically encountered in the posterior fossa of adults that show distinct epigenetic profiles assigned to the molecular group “subependymoma, posterior fossa” (PFSE) of the recently established DNA methylation-based classification of central nervous system tumors. In contrast, most posterior fossa ependymomas exhibit a more aggressive biological behavior and are allocated to the molecular subgroups PFA or PFB. A subset of ependymomas shows epigenetic similarities with subependymomas, but the precise biology of these tumors and their potential relationships remain unknown. We therefore set out to characterize epigenetic traits, mutational profiles, and clinical outcomes of 50 posterior fossa ependymal tumors of the PFSE group. On histo-morphology, these tumors comprised 12 ependymomas, 14 subependymomas and 24 tumors with mixed ependymoma–subependymoma morphology. Mixed ependymoma–subependymoma tumors varied in their extent of ependymoma differentiation (2–95%) but consistently exhibited global epigenetic profiles of the PFSE group. Selective methylome analysis of microdissected tumor components revealed CpG signatures in mixed tumors that coalesce with their pure counterparts. Loss of chr6 (20/50 cases), as well as TERT mutations (21/50 cases), were frequent events enriched in tumors with pure ependymoma morphology (p < 0.001) and confined to areas with ependymoma differentiation in mixed tumors. Clinically, pure ependymoma phenotype, chr6 loss, and TERT mutations were associated with shorter progression-free survival (each p < 0.001). In conclusion, our results suggest that subependymomas may acquire genetic and epigenetic changes throughout tumor evolution giving rise to subclones with ependymoma morphology (resulting in mixed tumors) that eventually overpopulate the subependymoma component (pure PFSE ependymomas). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00401-021-02300-8.